Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMay 26, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 19, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 17, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 16, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 10, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 4, 2017View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionMay 4, 2017View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
8-KReport of unscheduled material events or corporate eventMay 4, 2017View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesMay 1, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 27, 2017View HTMLDownload DOCDownload PDF
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 25, 2017View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveApr 25, 2017View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteApr 11, 2017View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesApr 6, 2017View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-144

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information